Financial Fraud in Indofarma
The BPK detected Rp371.83 billion worth of fund diversion at Indofarma. Money from a number of subsidiaries was siphoned off through problematic transactions.
Khairul Anam
June 3, 2024
AN audit by the Supreme Audit Agency (BPK) finally uncovered the rot within the management of Indofarma, a state-owned company engaged in the production of pharmaceuticals and medical equipment. At the end of 2023, state auditors conducted a special purpose audit (PDTT). During the initial audit, they found irregularities indicating criminal activities, otherwise known as fraud.
The BPK then raised the status of its audit of Indofarma and all it
...